| Previous Close | 137.97 |
| Open | 0.00 |
| Bid | 137.00 x 200 |
| Ask | 146.00 x 400 |
| Day's Range | 138.24 - 143.54 |
| 52 Week Range | 36.71 - 192.94 |
| Volume | 1,561,643 |
| Avg. Volume | 1,100,884 |
| Market Cap | 7.66B |
| Beta | 2.36 |
| PE Ratio (TTM) | -16.68 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Investor's Business Daily•2 days ago
Could Tesaro Overcome Clovis' Lead On Combos With Merck & Co.?
Tesaro's Zejula would likely outperform drugs from Clovis and AstraZeneca in immuno-oncology combinations with Merck, Bristol or Roche.
- Barrons.com•2 days ago
Biotech ETFs: Still Riding High
The biotechnology-stock rally continues. The SPDR S&P Biotech (XBI) and the iShares Nasdaq Biotechnology (IBB), among the highest-flying exchange-traded funds yesterday, both hit their 52-week highs on ...
- Zacks•2 days ago
Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study
Clovis Oncology, Inc. (CLVS) shares soared nearly 50% on Monday after it announced positive top-line results from a pivotal late-stage maintenance study on its newly launched ovarian cancer drug, Rubraca.
